Torrent Pharma. Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹4,979 Cr +50.8% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
TP

Torrent Pharma.

Q4 FY26Pharmaceuticals & Biotechnology

Torrent Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹4,197Cr
+41.8% YoY
+27.1% QoQ
Net profit
₹364Cr
−26.9% YoY
−42.7% QoQ
Margin
32%
−1 pp YoY
−1 pp QoQ
Price₹4,920
Market cap₹1.9L Cr
P/E83.5

The short version

Semaglutide launch expected to be significantly larger than any previous product launches; initial sales projected between INR 200-250 crores in the first year, notably higher than Sitagliptin's INR 70-75 crores launch in 2023. FY27 India organic growth expected to be mid-teens %, driven by Semaglutide, chronic segment outperformance, and new launches (Page 7).

From Torrent Pharma.'s Q4 FY26 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

  • Semaglutide launch expected to be significantly larger than any previous product launches; initial sales projected between INR 200-250 crores in the first year, notably higher than Sitagliptin's INR 70-75 crores launch in 2023.
  • India base business (excluding JB) grew 15% in Q4 FY26, expected to deliver mid-teens growth in FY27, barring external demand shocks.
  • Curatio business grew 27% in FY26, with strong outlook for continued traction driven by OTC advertising and field force expansion.
  • Brazil market projected to grow 10-15% CAGR over FY26-27 driven by new launches and price increases.
  • US business grew 31% INR growth in FY26, with expected single-digit growth on the back of single-digit product launches in FY27.
  • JB Pharma salesforce attrition improved; integration expected to enhance revenue synergies over next 2-3 years.

2 more points from Torrent Pharma.'s call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Torrent Pharma. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Torrent Pharma plans to increase R&D spend by approximately 0.5% of sales in the upcoming year, largely allocated to India and the US markets, focusing on existing business lines (Page 13).
  • There is interest in in-licensing products, especially from China and other markets, to expand opportunities in India (Page 6).
  • For the Semaglutide injectable business in India, potential future manufacturing in-house is considered if the product scales significantly (Page 14).

2 more points from Torrent Pharma.'s call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Torrent Pharma. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The discussion primarily focuses on: - Biosimilar business strategy and early-stage launches in Europe. - Sales and supply details around Semaglutide in India. - Revenue growth, R&D spends, and operational performance in India, Brazil, Germany, and the US.

2 more points from Torrent Pharma.'s call on order book

Create a free account to keep reading this call

Torrent Pharma. — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Torrent Pharma. Q4 FY26 results — key figures

Torrent Pharma. Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue4,1972,959+41.8%3,303+27.1%
Operating profit (EBITDA)1,356964+40.7%1,088+24.6%
Operating margin32%33%-1 pp33%-1 pp
Profit before tax529665-20.5%814-35%
Net profit (PAT)364498-26.9%635-42.7%
EPS (₹)10.7614.71-26.9%18.76-42.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹5.0K Cr, net profit ₹534 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Torrent Pharma. and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Torrent Pharma. Q4 FY26 results?

Semaglutide launch expected to be significantly larger than any previous product launches; initial sales projected between INR 200-250 crores in the first year, notably higher than Sitagliptin's INR 70-75 crores launch in 2023. FY27 India organic growth expected to be mid-teens %, driven by Semaglutide, chronic segment outperformance, and new launches (Page 7).

What is Torrent Pharma. share price analysis?

Torrent Pharma. currently shows a neutral. The stock trades at a P/E of 83.5 with a market cap of ₹186,247 Cr. Investors should review the full earnings analysis for detailed insights.

Is Torrent Pharma. planning capital expenditure?

Torrent Pharma plans to increase R&D spend by approximately 0.5% of sales in the upcoming year, largely allocated to India and the US markets, focusing on existing business lines (Page 13).

Keep Torrent Pharma. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.